"I would think having 70% tightly controlled is a positive for deal making, as long as the significant blocks are all aligned to ROI on the stock"

Buckeyes, maybe so for Ken Dart, seeing, that he closed his San Diego Neuroscience operation in 2018. But not so sure about Shenzhen Hepalink. They do have the licencing rights for Apabetalone. What they will do with it from here on end is the unknown. We just don't know what is going on behind closed doors in this regard.

IMO ... Koo